CTOs on the Move

Mindstrong Health

www.mindstronghealth.com

 
Mindstrong was founded by some of the world`s leading authorities in neuroscience, oncology, and technology. It is based on their shared vision to redefine neuropsychiatric healthcare, transforming diagnosis and delivering precision therapy. Mindstrong builds on one of the founder`s patented biomarker platform developed over years of extensive clinical R&D.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Mindstrong Health raised $14M on 06/15/2017
Mindstrong Health raised $15M on 06/14/2018
Mindstrong Health raised $30.9M on 12/21/2018

Similar Companies

BioSeek

BioSeek is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PAR Management

PAR Management is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Myriant Technologies

At Myriant, we know there`s a better, greener way to produce the products people use every day. And we`re realizing that vision—displacing barrels of petroleum by manufacturing and selling high-value chemicals made from renewable, sustainable feedstocks. As companies and consumers look for ways to reduce their carbon footprint and transition away from petroleum`s price volatility, Myriant has the solution: our proven technology platform and strategic feedstock selection enable Myriant to deliver high-quality, high-performing, green chemicals at a competitive, more-predictable cost versus petroleum-based chemicals without the need for government subsidies. That`s what we call a sustainable advantage.

Annexon Biosciences

Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders of the body, brain and eye. The company`s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration) and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio.

Seagen

Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer.